<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1282">
  <stage>Registered</stage>
  <submitdate>3/09/2006</submitdate>
  <approvaldate>3/09/2006</approvaldate>
  <nctid>NCT00372086</nctid>
  <trial_identification>
    <studytitle>Rosiglitazone and Insulin in T1DM Adolescents</studytitle>
    <scientifictitle>The Addition of Rosiglitazone to Insulin in Adolescents With Type 1 Diabetes and Poor Glycaemic Control: a Randomized, Placebo Controlled Trial</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>JHH ethics: 04/02/11/3.04</secondaryid>
    <secondaryid>02/315</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Type 1 Diabetes</healthcondition>
    <healthcondition>Puberty: &gt;Tanner 2 Breast Development or Testis &gt;4ml</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Rosiglitazone

Treatment: drugs: Rosiglitazone


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>HbA1c</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>insulin dose</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>frequency of severe hypoglycaemia</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>insulin sensitivity assessed by euglycaemic, hyperinsulinaemic clamp</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>weight</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>BMI-SDS</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>skin fold thickness</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>cholesterol</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>adiponectin</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  T1DM duration &gt; 1year

          -  age 10-18years

          -  HbA1c &gt; 8%

          -  puberty &gt; Tanner stage 2 breast or testis &gt;4ml</inclusivecriteria>
    <inclusiveminage>10</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>18</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer />
    <exclusivecriteria>-  known non-compliance

          -  hypo unaware</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2003</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Sydney Children's Hospital - Sydney</hospital>
    <postcode>2038 - Sydney</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>The University of New South Wales</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Sydney Children's Hospitals Network</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>National Health and Medical Research Council, Australia</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Novo Nordisk A/S</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Type 1 Diabetes is the most common life-long disorder with onset in childhood. Patients need
      insulin injections, blood sugar monitoring several times each day, and adhere to a strict
      diet. Adequate control of blood glucose is essential to prevent long term kidney and eye
      complications that result in kidney failure and blindness. Adolescence is a time when
      diabetes is difficult to control, due in part to high growth hormone levels causing insulin
      resistance ( a state where the body does not respond as strongly to insulin). This study will
      test whether treatment with rosiglitazone (an oral medication used frequently in type 2
      diabetes) will reduce the insulin resistance of adolescence and improve the control of type 1
      diabetes during puberty.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00372086</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Monique Stone, MBBS FRACP</name>
      <address>Royal North Shore Hospital</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>